Veterinary Anesthetic Alfaxan Approved for U.S. Distribution

Alfaxan (alfaxalone 10 mg/mL) is approved for use in cats and dogs.

Each milliliter of Alfaxan contains 10 milligrams of the active ingredient alfaxalone.

An intravenous injectable anesthetic commonly used in Australia will be released to U.S. veterinarians Aug. 25, the manufacturer, Jurox Animal Health, reported.

Alfaxan (alfaxalone 10 mg/mL) is approved for use in cats and dogs. The drug is indicated for the induction and maintenance of anesthesia and for the induction of anesthesia followed by maintenance with an inhalant anesthetic.

Winning U.S. Food and Drug Administration approval of Alfaxan took time, said JJ O’Brien, CEO of Australia-based Jurox.

“Since beginning this process, we have had countless inquiries as to why it has not been available to U.S. veterinarians,” O’Brien said.

The drug is widely accepted by Australian veterinarians and has been used in 20 countries.

“An independent study commissioned by Jurox reported Australian veterinarians to rely on Alfaxan for induction as often as 74 percent of the time in cats and 52 percent in dogs,” the company stated.

Alfaxan’s U.S. distributors will include Henry Schein Animal Health, MWI Veterinary Supply, Patterson Veterinary Supply, NEVSCo, Midwest Veterinary Supply and Victor Medical Co.

Jurox earlier this summer opened its U.S. headquarters in Kansas City, Mo.

Leave a Comment

Comments

Your email address will not be published. Required fields are marked *

___

Register

Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).
 

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.